A paper by Dr. Tomoka Hasegawa of Hokkaido University’s Faculty of Dental Medicine has been published in Journal of Oral Biosciences.
- Akito Makino, Tomoka Hasegawa, Tomomaya Yamamoto, Hideko Takagi, Takeshi Iijima, Norio Amizuka. Abaloparatide increases bone mass by increasing bone formation regardless of alendronate pretreatment in mice. Journal of Oral Biosciences, Volume 68, Issue 1, 2026, 100708, ISSN 1349-0079,
DOI: https://doi.org/10.1016/j.job.2025.100708
Abstract
The effects of bisphosphonate pretreatment on the bone anabolic effects of abaloparatide (ABL) in mice were investigated. Mice were administered alendronate (ALN) at different doses for 21 days, followed by 28 days of ABL. ABL increased femoral bone mineral density at all ALN doses, with effects equal to or greater than those observed in mice without ALN. Histological analysis demonstrated that ABL increased ALPase- and PHOSPHO1-positive osteoblasts, irrespective of ALN pretreatment. However, the increase in TRAP-positive osteoclasts by ABL was attenuated at higher ALN doses. These findings suggest that ABL promotes bone formation in mice, independently of ALN pretreatment.
Keywords: Abaloparatide; Alendronate; Switch therapy; Bone formation; Animal experiment
Credit: Makino, A., Hasegawa, T., Yamamoto, T., Takagi, H., Iijima, T., & Amizuka, N. (2026). Abaloparatide increases bone mass by increasing bone formation regardless of alendronate pretreatment in mice. Journal of Oral Biosciences, 68(1), 100708. https://doi.org/10.1016/j.job.2025.100708 Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).